Glenmark Pharmaceuticals Limited: Aims To Grow Its Respiratory Products In FY27; Winlevi® Has Gained EU Approval With A Launch Planned For FY27, And Aumolertinib's Initial Launch Is Anticipated In H2 FY27.

 30 May 2026 03:07 PM

Glenmark Pharmaceuticals Limited: Aims To Grow Its Respiratory Products In FY27; Winlevi® Has Gained EU Approval With A Launch Planned For FY27, And Aumolertinib's Initial Launch Is Anticipated In H2 FY27.

GLENMARK PHARMA: Q4 CONS NET PROFIT 3B RUPEES VS 465M (YOY) || Q4 REVENUE 37.6B RUPEES VS 32.6B (YOY)

 29 May 2026 08:25 PM

GLENMARK PHARMA: Q4 CONS NET PROFIT 3B RUPEES VS 465M (YOY) || Q4 REVENUE 37.6B RUPEES VS 32.6B (YOY)

GLENMARK PHARMA: Q4 EBITDA 9.4B RUPEES VS 5.6B (YOY) || Q4 EBITDA MARGIN 25% VS 17.23% (YOY)

 29 May 2026 08:25 PM

GLENMARK PHARMA: Q4 EBITDA 9.4B RUPEES VS 5.6B (YOY) || Q4 EBITDA MARGIN 25% VS 17.23% (YOY)

Glenmark Pharma: Joint Venture IGI Introduces ISB 2301, A Novel Immune Cell Activator For Treating Various Solid Tumors.

 20 May 2026 04:25 PM

Glenmark Pharma: Joint Venture IGI Introduces ISB 2301, A Novel Immune Cell Activator For Treating Various Solid Tumors.

Glenmark Pharmaceuticals: Introduces Vancomycin Hydrochloride Injection In 500 MG And 1 G Vials In The U.S.; Product Matches Fresenius Kabi's Drug; Market Sales Hit $37.9 Million.

 18 May 2026 09:04 AM

Glenmark Pharmaceuticals: Introduces Vancomycin Hydrochloride Injection In 500 MG And 1 G Vials In The U.S.; Product Matches Fresenius Kabi's Drug; Market Sales Hit $37.9 Million.

Glenmark Pharma: U.S. FDA Approves 100 Mg Progesterone Vaginal Inserts, Drug Sales Hit About $59 Million Per Year

 09 Apr 2026 08:59 AM

Glenmark Pharma: U.S. FDA Approves 100 Mg Progesterone Vaginal Inserts, Drug Sales Hit About $59 Million Per Year

Glenmark Pharmaceuticals: Company Starts Direct U.S. Sales Of Ryaltris, Growing Its Innovative Product Line

 01 Apr 2026 05:39 PM

Glenmark Pharmaceuticals: Company Starts Direct U.S. Sales Of Ryaltris, Growing Its Innovative Product Line

GLENMARK PHARMACEUTICALS: CO LAUNCHES GLIPIQ® (SEMAGLUTIDE) IN INDIA || SETTING A NEW BENCHMARK IN AFFORDABILITY FOR GLP-1 THERAPY, WITH WEEKLY TREATMENT STARTING AT ₹325.

 21 Mar 2026 10:01 AM

GLENMARK PHARMACEUTICALS: CO LAUNCHES GLIPIQ® (SEMAGLUTIDE) IN INDIA || SETTING A NEW BENCHMARK IN AFFORDABILITY FOR GLP-1 THERAPY, WITH WEEKLY TREATMENT STARTING AT ₹325.

Glenmark Pharma: Glenmark Pharmaceuticals Inc. Launches Milnacipran Hydrochloride Tablets, A Generic Version Of Savella, In The U.S. Market Worth $103 Million

 19 Mar 2026 08:47 AM

Glenmark Pharma: Glenmark Pharmaceuticals Inc. Launches Milnacipran Hydrochloride Tablets, A Generic Version Of Savella, In The U.S. Market Worth $103 Million

Glenmark Pharma: Gets US FDA Approval For Fluticasone Nasal Spray Aiming At $384 Million OTC Market.

 19 Mar 2026 08:40 AM

Glenmark Pharma: Gets US FDA Approval For Fluticasone Nasal Spray Aiming At $384 Million OTC Market.

Glenmark Pharma: Glenmark Pharmaceuticals Inc., USA Is Set To Release Potassium Phosphates Injection In The US, With Annual Sales Nearing USD 50.7 Million.

 16 Mar 2026 08:55 AM

Glenmark Pharma: Glenmark Pharmaceuticals Inc., USA Is Set To Release Potassium Phosphates Injection In The US, With Annual Sales Nearing USD 50.7 Million.

Glenmark Pharmaceuticals: HSBC maintains Buy on Glenmark Pharmaceuticals with Target Price Rs 2,600 (raised), citing USFDA approval of gFlovent 44mcg inhaler improving US sales trajectory, with learnings aiding gFlovent 110mcg ANDA review, and consistent new US approvals seen as the key catalyst.

 11 Mar 2026 09:05 AM

Glenmark Pharmaceuticals: HSBC maintains Buy on Glenmark Pharmaceuticals with Target Price Rs 2,600 (raised), citing USFDA approval of gFlovent 44mcg inhaler improving US sales trajectory, with learnings aiding gFlovent 110mcg ANDA review, and consistent new US approvals seen as the key catalyst.

Glenmark Pharma: Glenmark Specialty Wins U.S. FDA Approval For Fluticasone Propionate Inhalation Aerosol, 44 Mcg Per Actuation, With 180-Day Exclusive Generic Competition. Annual Sales Reach About USD 520 Million

 04 Mar 2026 08:44 AM

Glenmark Pharma: Glenmark Specialty Wins U.S. FDA Approval For Fluticasone Propionate Inhalation Aerosol, 44 Mcg Per Actuation, With 180-Day Exclusive Generic Competition. Annual Sales Reach About USD 520 Million

Glenmark Pharmaceuticals: Plans Launch Of Sodium Phosphates Injection USP In Three Forms Starting April 2026, With An Expected Market Size Of $66.8 Million

 27 Feb 2026 09:21 AM

Glenmark Pharmaceuticals: Plans Launch Of Sodium Phosphates Injection USP In Three Forms Starting April 2026, With An Expected Market Size Of $66.8 Million

Glenmark Pharma: Plans To Achieve 115 Days Of Net Working Capital By March '26, Currently At About 110 Days, And Aims To Have Zero Gross Debt By March '26. The Company Expects Annual Capital Expenditure Of INR 700-800 Crores, With INR 800 Crores Slated For Next Year Mainly For Plant Expansion And In-Licensing.

 03 Feb 2026 09:01 AM

Glenmark Pharma: Plans To Achieve 115 Days Of Net Working Capital By March '26, Currently At About 110 Days, And Aims To Have Zero Gross Debt By March '26. The Company Expects Annual Capital Expenditure Of INR 700-800 Crores, With INR 800 Crores Slated For Next Year Mainly For Plant Expansion And In-Licensing.

Glenmark: Expects Strong End To FY26 And Good Start To "Glenmark 3.0" Growth Journey In 2027, Aiming To Meet Overall Goals. Company Targets Sustainable EBITDA Margin Of 23% For This Year and Coming Quarters, Expecting Significant Margin Increase From FY28 Due To New Innovations

 03 Feb 2026 09:01 AM

Glenmark: Expects Strong End To FY26 And Good Start To "Glenmark 3.0" Growth Journey In 2027, Aiming To Meet Overall Goals. Company Targets Sustainable EBITDA Margin Of 23% For This Year and Coming Quarters, Expecting Significant Margin Increase From FY28 Due To New Innovations

Glenmark Pharma: Plans Expansion With New Approvals. The US division anticipates strong growth in Q4 FY26 from respiratory product launches, including a probable FloVent 44 approval, while the Monroe site will begin commercial production in the same quarter, aiming for three annual filings. New product approvals are expected in Q4, which may boost gross margins.

 03 Feb 2026 09:02 AM

Glenmark Pharma: Plans Expansion With New Approvals. The US division anticipates strong growth in Q4 FY26 from respiratory product launches, including a probable FloVent 44 approval, while the Monroe site will begin commercial production in the same quarter, aiming for three annual filings. New product approvals are expected in Q4, which may boost gross margins.

Glenmark Pharma: Seeks Regulatory Approvals with Two ANDAs Submitted for North America in Q3 and Three More Planned for Next Quarter, Including Generic Flovent 110 and Two Generic Nasal Sprays.

 03 Feb 2026 09:02 AM

Glenmark Pharma: Seeks Regulatory Approvals with Two ANDAs Submitted for North America in Q3 and Three More Planned for Next Quarter, Including Generic Flovent 110 and Two Generic Nasal Sprays.

GLENMARK PHARMA: Q3 CONS NET PROFIT 4B RUPEES VS 3.5B (YOY); EST 6.3B || Q3 REVENUE 39B RUPEES VS 33B (YOY)

 30 Jan 2026 08:13 PM

GLENMARK PHARMA: Q3 CONS NET PROFIT 4B RUPEES VS 3.5B (YOY); EST 6.3B || Q3 REVENUE 39B RUPEES VS 33B (YOY)

GLENMARK PHARMA: Q3 EBITDA 9B RUPEES VS 6B (YOY) || Q3 EBITDA MARGIN 23.19% VS 18.18% (YOY)

 30 Jan 2026 08:14 PM

GLENMARK PHARMA: Q3 EBITDA 9B RUPEES VS 6B (YOY) || Q3 EBITDA MARGIN 23.19% VS 18.18% (YOY)